OctoPlus and Biolex Announce Joint Development of Locteron

OctoPlus, the drug delivery and development company and Biolex Inc., a protein therapeutics company, announced today that they have entered into collaboration for co-development of a controlled release formulation of recombinant human alfa interferon. The product, named Locteron, combines OctoPlus' proprietary biodegradable PolyActive drug delivery technology with Biolex' BLX-883, a recombinant alfa interferon produced in its proprietary LEX System.

Yahoo News (http://biz.yahoo.com/prnews/050216/ukw010_1.html)